| Name | Rovazolac |
|---|---|
| Synonyms |
Ethyl {5-[3'-(methylsulfonyl)-4-biphenylyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl}acetate
W51K389XIL rovazolac 1H-Pyrazole-1-acetic acid, 5-[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-, ethyl ester |
| Description | Rovazolac is a liver x receptor (LXR) modulator extracted from patent WO2013130892A1. |
|---|---|
| Related Catalog | |
| Target |
Target: LXR[1] |
| In Vitro | Rovazolac is an anti-inflammatory drug candidate[1]. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 625.8±55.0 °C at 760 mmHg |
| Molecular Formula | C21H19F3N2O4S |
| Molecular Weight | 452.447 |
| Flash Point | 332.3±31.5 °C |
| Exact Mass | 452.101776 |
| LogP | 4.02 |
| Vapour Pressure | 0.0±1.8 mmHg at 25°C |
| Index of Refraction | 1.570 |
| Storage condition | 2-8℃ |